share_log

Shattuck Labs | 8-K: Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs | 8-K: Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs | 8-K：Shattuck Labs公布2024年第一季度财务业绩和近期业务亮点
美股sec公告 ·  05/02 07:03
Moomoo AI 已提取核心信息
On May 2, 2024, Shattuck Labs, Inc., a clinical-stage biotechnology company, reported its financial results for the first quarter ending March 31, 2024. The company, which specializes in developing bi-functional fusion proteins for cancer and autoimmune disease treatment, announced rapid enrollment in the expanded TP53 mutant Acute Myeloid Leukemia cohort and plans to initiate enrollment for a randomized cohort in Higher-Risk Myelodysplastic Syndromes in Q2 2024. Shattuck also presented preclinical data at the AACR Annual Meeting, highlighting the potential of TRIM7 inhibition in overcoming resistance to immune checkpoint therapy. Financially, Shattuck reported a decrease in net loss to $18.5 million for Q1 2024 from $20.7 million in Q1 2023, with cash and investments totaling $114.6 million, which is expected to fund operations into 2026. The company also appointed two new members to its Board of Directors and continued to advance its pre-clinical pipeline, including a strategic collaboration with Ono Pharmaceutical for autoimmune and inflammatory diseases.
On May 2, 2024, Shattuck Labs, Inc., a clinical-stage biotechnology company, reported its financial results for the first quarter ending March 31, 2024. The company, which specializes in developing bi-functional fusion proteins for cancer and autoimmune disease treatment, announced rapid enrollment in the expanded TP53 mutant Acute Myeloid Leukemia cohort and plans to initiate enrollment for a randomized cohort in Higher-Risk Myelodysplastic Syndromes in Q2 2024. Shattuck also presented preclinical data at the AACR Annual Meeting, highlighting the potential of TRIM7 inhibition in overcoming resistance to immune checkpoint therapy. Financially, Shattuck reported a decrease in net loss to $18.5 million for Q1 2024 from $20.7 million in Q1 2023, with cash and investments totaling $114.6 million, which is expected to fund operations into 2026. The company also appointed two new members to its Board of Directors and continued to advance its pre-clinical pipeline, including a strategic collaboration with Ono Pharmaceutical for autoimmune and inflammatory diseases.
2024年5月2日，处于临床阶段的生物技术公司Shattuck Labs, Inc. 公布了截至2024年3月31日的第一季度财务业绩。该公司专门开发用于癌症和自身免疫性疾病治疗的双功能融合蛋白，宣布快速注册扩大的TP53突变体急性髓系白血病队列，并计划在2024年第二季度启动高风险骨髓增生异常综合征随机队列的入组。沙特克还在 AACR 年会上公布了临床前数据，强调了 TRIM7 抑制在克服免疫检查点疗法耐药性方面的潜力。财务方面，沙特克报告称，净亏损从2023年第一季度的2,070万美元下降至2024年第一季度的1,850万美元，现金和投资总额为1.146亿美元，预计将为2026年的运营提供资金。公司还任命了两名新董事会成员，并继续推进其临床前产品线，包括与小野制药在自身免疫和炎症性疾病方面的战略合作。
2024年5月2日，处于临床阶段的生物技术公司Shattuck Labs, Inc. 公布了截至2024年3月31日的第一季度财务业绩。该公司专门开发用于癌症和自身免疫性疾病治疗的双功能融合蛋白，宣布快速注册扩大的TP53突变体急性髓系白血病队列，并计划在2024年第二季度启动高风险骨髓增生异常综合征随机队列的入组。沙特克还在 AACR 年会上公布了临床前数据，强调了 TRIM7 抑制在克服免疫检查点疗法耐药性方面的潜力。财务方面，沙特克报告称，净亏损从2023年第一季度的2,070万美元下降至2024年第一季度的1,850万美元，现金和投资总额为1.146亿美元，预计将为2026年的运营提供资金。公司还任命了两名新董事会成员，并继续推进其临床前产品线，包括与小野制药在自身免疫和炎症性疾病方面的战略合作。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息